1. Home
  2. CAAS vs CRBU Comparison

CAAS vs CRBU Comparison

Compare CAAS & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CAAS

China Automotive Systems Inc.

HOLD

Current Price

$5.00

Market Cap

134.9M

ML Signal

HOLD

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$1.25

Market Cap

138.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAAS
CRBU
Founded
N/A
2011
Country
China
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.9M
138.3M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
CAAS
CRBU
Price
$5.00
$1.25
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $10.75
AVG Volume (30 Days)
19.3K
★ 1.1M
Earning Date
04-22-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 3.64
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.63
Revenue Next Year
N/A
$10.93
P/E Ratio
$3.97
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.00
$1.25
52 Week High
$5.64
$3.53

Technical Indicators

Market Signals
Indicator
CAAS
CRBU
Relative Strength Index (RSI) 43.25 33.15
Support Level $4.39 N/A
Resistance Level $5.00 $1.76
Average True Range (ATR) 0.17 0.07
MACD -0.06 -0.01
Stochastic Oscillator 0.87 6.94

Price Performance

Historical Comparison
CAAS
CRBU

About CAAS China Automotive Systems Inc.

China Automotive Systems Inc is a holding company. The firm, through its subsidiary, is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series of power steering models, including rack and pinion power steering, integral power steering, electronic power steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Share on Social Networks: